Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Net Cash Flow (2017 - 2025)

Arcus Biosciences has reported Net Cash Flow over the past 9 years, most recently at -$16.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$16.0 million for Q4 2025, up 68.63% from a year ago — trailing twelve months through Dec 2025 was $72.0 million (up 213.04% YoY), and the annual figure for FY2025 was $72.0 million, up 213.04%.
  • Net Cash Flow for Q4 2025 was -$16.0 million at Arcus Biosciences, down from -$10.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for RCUS hit a ceiling of $401.0 million in Q1 2022 and a floor of -$276.0 million in Q2 2022.
  • Median Net Cash Flow over the past 5 years was -$14.0 million (2022), compared with a mean of $2.6 million.
  • Biggest five-year swings in Net Cash Flow: soared 2228.58% in 2021 and later plummeted 375.0% in 2023.
  • Arcus Biosciences' Net Cash Flow stood at -$31.8 million in 2021, then skyrocketed by 62.29% to -$12.0 million in 2022, then plummeted by 375.0% to -$57.0 million in 2023, then grew by 10.53% to -$51.0 million in 2024, then skyrocketed by 68.63% to -$16.0 million in 2025.
  • The last three reported values for Net Cash Flow were -$16.0 million (Q4 2025), -$10.0 million (Q3 2025), and $56.0 million (Q2 2025) per Business Quant data.